CagriSema REDEFINE 1: The Published Evidence Behind Combination Weight Management

The 68-week Phase 3 REDEFINE 1 clinical trial results represent the primary registrational milestone for CagriSema in non-diabetic chronic weight management. By evaluating the co-formulated amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide against its individual monotherapy components and placebo in 3,417 adults, the trial provides definitive, peer-reviewed proof of how dual neuroendocrine satiety pathways operate to exceed single-incretin weight-loss ceilings.

What Is the Compound? Mechanism of Dual Amylin and GLP-1 Co-Formulation

CagriSema is an investigational, fixed-dose co-formulation combining two distinct long-acting peptide analogues into a single weekly subcutaneous autoinjector: the selective amylin analogue cagrilintide (2.4 mg) and the established GLP-1 receptor agonist semaglutide (2.4 mg). In metabolic pharmacology, simply combining two active drugs does not guarantee therapeutic synergy; pharmaceutical co-formulations must prove in factorial trials that combining targets produces greater benefit than escalating either component alone.

The biological rationale for pairing cagrilintide with semaglutide coordinates appetite suppression through two distinct neuroanatomical circuits:

• Semaglutide (GLP-1 Receptor Pathway): Acts primarily on the hypothalamic arcuate nucleus, autonomic brainstem nuclei, and gastrointestinal tracts, stimulating glucose-dependent pancreatic insulin release, delaying gastric transit, and blunting hedonic food cravings.
• Cagrilintide (Dual Amylin/Calcitonin Receptor Pathway): Mimics native human amylin, a 37-amino-acid neuroendocrine hormone naturally co-secreted with insulin by pancreatic beta cells. Cagrilintide binds calcitonin receptor core complexes coupled with receptor activity-modifying proteins (AMY1–3) in the area postrema and nucleus of the solitary tract (NTS) in the caudal hindbrain, driving homeostatic meal satiation and suppressing inappropriate mealtime glucagon surges without causing hypoglycemia.
• Engineered Solution Co-Crystallization: CagriSema is a precision-engineered liquid formulation developed to ensure identical chemical stability, solubility, and synchronized subcutaneous bioavailability. These clinical outcomes cannot be replicated by compounding independent peptides or manually mixing separate vials in a clinical setting.

By engaging the hypothalamus (GLP-1) and the caudal hindbrain (amylin) simultaneously, CagriSema coordinates energy regulation across complementary neural pathways, driving deep weight loss without exceeding the physiological tolerance ceiling of either individual hormone.

How the Study Worked: REDEFINE 1 Factorial Architecture

The REDEFINE 1 study was engineered as a large-scale, prospective, randomized, double-blind, active-controlled Phase 3 trial to rigorously test the added value of the combination against each constituent component in a shared clinical setting:

Complete clinical protocol parameters and peer-reviewed disclosures are documented in the REDEFINE 1 Primary Study Report (PubMed).

Results and Key Findings: Surpassing Single-Incretin Ceilings

The 68-week published data from REDEFINE 1 demonstrated that combining amylin and GLP-1 receptor agonism produces statistically superior weight reduction compared to each monotherapy component:

• The 20.4% Treatment-Policy Estimand (ITT): In the primary regulatory analysis—which evaluates all randomized participants regardless of whether they adhered to dosing, discontinued early, or initiated rescue interventions—CagriSema delivered a 20.4% mean body weight reduction, compared to 3.0% for placebo, 14.9% for semaglutide monotherapy, and 11.8% for cagrilintide monotherapy (p < 0.0001 for all comparisons).
• The 22.7% Trial-Product Estimand (Adherent): Under the on-treatment efficacy model—evaluating participants who remained fully adherent without treatment disruption—CagriSema achieved an average body weight reduction of 22.7% (versus 2.8% on placebo, 16.7% for semaglutide, and 13.2% for cagrilintide). Both estimands confirm high-tier metabolic efficacy while answering distinct clinical questions.
• High-Tier Categorical Responders: Approximately 88.4% of patients receiving CagriSema achieved ≥10% weight loss, 73.1% achieved ≥15% weight loss, and 53.8% achieved ≥20% weight loss, demonstrating substantial responder depth across the cohort.
• Factorial Proof of Synergy: Because CagriSema outperformed both semaglutide monotherapy (+5.5% net ITT difference) and cagrilintide monotherapy (+8.6% net ITT difference) within the identical study cohort, the trial provides mathematical proof of component synergy.

The Study in Plain English: Understanding Trial Estimands & Weight Metrics

Interpreting clinical trials in obesity pharmacotherapy requires understanding the distinction between statistical reporting models and real-world outcomes:

Key Insights: What Makes the REDEFINE 1 Readout Landmark?

The clinical contribution of REDEFINE 1 provides vital clarity for endocrinologists and researchers navigating multi-hormone therapeutics:

• Breaking the Monotherapy Incretin Ceiling: In landmark Phase 3 trials, maximum-dose single-incretin therapy (subcutaneous semaglutide 2.4 mg in STEP 1) established a benchmark of approximately 14.9% ITT and 16.9% on-treatment weight loss. Achieving 20.4% ITT and 22.7% on-treatment weight loss proves that adding amylin agonism breaks through this single-pathway efficacy plateau.
• Rigorous Factorial Proof Over Speculation: Pharmaceutical discussions often debate combinations based on theoretical biology. REDEFINE 1 evaluated the combination against its isolated components within a 3,417-patient cohort, demonstrating that both peptides are required to achieve the full 22.7% efficacy response.
• Differentiating Obesity from Diabetes Outcomes: Crucially, these non-diabetic results must be interpreted independently from REDEFINE 2, where diabetic cohorts achieved 13.7% ITT loss. Non-diabetic populations consistently achieve higher percentage drops due to the absence of insulin-mediated anabolic resistance.

Tolerability & The Complete Safety Profile

Throughout the 68-week evaluation period, CagriSema exhibited an adverse-event profile consistent with combined incretin and amylin receptor agonism, highlighting predictable gastrointestinal dynamics:

• Gastrointestinal Event Frequency: Treatment-emergent gastrointestinal adverse events were reported in 79.6% of patients receiving CagriSema, compared to 39.9% in the placebo group, 70.8% with semaglutide monotherapy, and 63.8% with cagrilintide monotherapy. The vast majority of events consisted of mild-to-moderate nausea, constipation, and diarrhea occurring primarily during stepped dose escalation.
• Severity vs. Frequency: Describing gastrointestinal events as predominantly mild or moderate refers to clinical severity, not frequency. Because nearly 80% of participants reported gastrointestinal symptoms, patient education and gradual dose escalation remain critical to clinical management.
• Treatment Discontinuation Rates: Discontinuations resulting from adverse events occurred in 10.0% of CagriSema-treated patients versus 4.4% in the placebo group, 7.3% with semaglutide, and 5.7% with cagrilintide, reflecting the expected tolerability tradeoff of dual neuroendocrine appetite suppression.

For complete safety data disclosures and subgroup tables, reference the REDEFINE 1 Primary Peer-Reviewed Publication (PubMed).

Comparative Research Themes & Next-Generation Metabolic Pipelines

To contextualize CagriSema within the broader landscape of obesity pharmacotherapy, researchers compare multi-receptor mechanisms across Phase 3 programs:

For a detailed analysis of comparative amylin biology, explore our guide: Eloralintide vs Cagrilintide: Amylin Agonists Compared. To review data in patients with type 2 diabetes managed with oral agents, read: CagriSema REDEFINE 2 Results: Phase 3 Diabetes Trial Data. To examine lower-dose optimization, read: CagriSema REDEFINE 9 Results: Lower-Dose Phase 3 Trial Data.

What Patients and Clinicians Can Look Forward To

CagriSema remains an investigational combination therapy undergoing active global Phase 3 evaluation; it is not yet approved by the U.S. FDA or international health authorities. However, the peer-reviewed publication of REDEFINE 1 provides the core safety and efficacy package required for regulatory submission.

For clinicians and patients, these findings introduce the prospect of a once-weekly fixed-dose combination capable of achieving over 20% weight reduction. If approved, CagriSema will offer a dual-hormone option that addresses appetite dysregulation across both the hypothalamus and the hindbrain, expanding therapeutic choices beyond single-agent GLP-1 therapies.

Questions for the Next Stage of Research

While the 68-week REDEFINE 1 findings establish clear proof-of-concept, several vital clinical questions guide ongoing evaluation:

• Long-Term Multi-Year Maintenance: Will participants who achieve 22.7% weight loss maintain that reduction through years 2, 3, and 5 of continuous therapy without experiencing late metabolic plateauing?
• Cardiovascular and Microvascular Outcomes: Will co-formulating cagrilintide with semaglutide preserve or amplify the proven cardiovascular and renal protections established by semaglutide monotherapy in the SELECT and FLOW trials?
• Preservation of Lean Muscle Mass: What exact proportion of the weight reduction achieved under dual amylin/GLP-1 agonism represents adipose tissue versus lean skeletal muscle mass during prolonged therapy?

Explore Our Research Tools

To assist laboratory scientists and clinicians in tracking peptide calculations, experimental schedules, and analytical observations, explore our specialized software suite:

• Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
• Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
• Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.

Scientific References & Primary Trial Documents

• REDEFINE 1 Primary Study Report: CagriSema vs Semaglutide, Cagrilintide, and Placebo in Adults with Overweight or Obesity (PubMed)
• CagriSema REDEFINE 2 Results: Phase 3 Diabetes Trial Data
• CagriSema REDEFINE 9 Results: Lower-Dose Phase 3 Trial Data
• Eloralintide vs Cagrilintide: Amylin Agonists Compared